Welcome to our dedicated page for Immunitybio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImmunityBio, Inc. (NASDAQ: IBRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including annual reports, quarterly reports, and current reports on Form 8‑K. As a commercial-stage biotechnology issuer focused on IL‑15–based immunotherapies and cell therapies, ImmunityBio uses these filings to report financial performance, capital structure changes, governance matters, and material agreements related to its ANKTIVA‑centered portfolio.
Annual reports (Form 10‑K) and quarterly reports (Form 10‑Q) detail product revenue from ANKTIVA, research and development spending on programs such as QUILT‑3.032 in non‑muscle invasive bladder cancer and QUILT‑2.023/3.055 in non‑small cell lung cancer, and broader risk factors associated with developing and commercializing biologic therapies. These filings also summarize segment information, which the company describes as including the United States and Europe, and discuss liquidity, debt obligations, and equity plans.
Current reports (Form 8‑K) capture specific material events. Recent 8‑Ks disclose an at‑the‑market offering program amendment authorizing additional common stock sales under a shelf registration statement, a registered direct offering of common shares and warrants, adoption of the 2025 Equity Incentive Plan, and the appointment of independent directors. Other 8‑Ks reference earnings press releases that report net product revenue growth for ANKTIVA and changes in cash, cash equivalents, and marketable securities.
Investors interested in capital markets activity can review filings describing increases in authorized common stock, revenue interest liabilities, and equity incentive structures. Governance‑focused readers can examine disclosures on board composition, director compensation policies, and the preliminary approval of a settlement of stockholder derivative actions that includes corporate governance reforms.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language. Instead of parsing lengthy 10‑K or 10‑Q documents line by line, users can see concise overviews of ImmunityBio’s revenue trends, R&D priorities, financing arrangements, and risk disclosures, then drill down into the original SEC documents when more detail is needed.
For those tracking IBRX insider and executive activity, forms such as Form 4 and proxy‑related materials (when available) provide insight into equity awards, option grants, and ownership changes, complementing the broader financial and operational picture presented in periodic reports.
ImmunityBio, Inc. director Simon Barry J. reported two open-market sales of common stock. On January 20, 2026, he sold 76,967 shares at $6.54 per share and 75,000 shares at a weighted average price of $7.8791 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024. Following the reported sales, he directly beneficially owned 3,091,604 shares of ImmunityBio common stock.
ImmunityBio, Inc. director Christobel Selecky reported option exercises and share sales in January 2026. On January 16, 2026, she exercised 50,000 stock options with a $2.98 exercise price for common stock and then sold 50,000 shares at $5.00 per share, leaving her with no directly held common stock after the sale. On January 20, 2026, she exercised an additional 25,000 stock options at $2.98 and sold 25,000 shares at a weighted average price of $7.50 to $7.52, again ending with no directly held common shares.
The Form 4 shows that after these transactions, she continued to hold stock options, with 117,937 options remaining after the first exercise and 92,937 options after the second. All of the option shares had fully vested on June 12, 2023, and the options are scheduled to expire on June 14, 2032. The filing notes that the reported sales were made under a Rule 10b5-1 trading plan that she adopted on June 12, 2025, indicating the transactions were pre-arranged rather than opportunistic.
A shareholder of IBRX has filed a Form 144 notice for a proposed sale of 25,000 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ market. The filing lists an aggregate market value of $138,000 for these shares and an approximate sale date of 01/20/2026.
The shares to be sold were acquired on 01/20/2026 by exercising stock options granted by the issuer, with cash used as payment for the 25,000 shares. The issuer had 984,965,179 shares outstanding. The filing also discloses that during the prior three months, a Rule 10b5-1 trading plan for Christobel Selecky sold 50,000 common shares for $250,000 in gross proceeds.
A shareholder has filed a Form 144 notice to sell 571,967 shares of common stock through The Charles Schwab Corporation on NASDAQ. The proposed sale has an aggregate market value of $5,909,546.00, with an approximate sale date of 01/20/2026. The filing indicates these shares were acquired from the issuer on 12/31/2013 by various methods and dates, with the full 571,967 shares acquired and paid for on that date. The table also shows that 984,965,179 shares of this class of common stock are outstanding. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
A holder of ImmunityBio (symbol IBRX) has filed a Rule 144 notice to sell 50,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $197,500 based on the figures in the notice. The filing lists 984,965,179 shares outstanding as a baseline figure for the issuer’s common stock.
The securities to be sold were acquired on 01/16/2026 by an exercise of stock options from the issuer, paid in cash, with the same date shown for payment. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, consistent with the representations referenced in Rule 144 and any Rule 10b5-1 trading plan disclosures.
ImmunityBio, Inc. filed a current report to disclose that it issued a press release with certain preliminary, unaudited financial results for the fiscal quarter and full year ended December 31, 2025, along with other company updates. These figures are based on information available as of the press release date and are not a comprehensive statement of its operating results or financial position.
The company notes that final results to be reported in its Annual Report on Form 10-K for the year ended December 31, 2025 will follow normal financial closing procedures and may differ materially from the preliminary estimates. The press release is furnished, not filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings unless specifically referenced.
ImmunityBio, Inc. reported that the Saudi Food and Drug Authority has granted accelerated approval for its immunotherapy ANKTIVA in two cancer indications. ANKTIVA was approved for use with immune checkpoint inhibitors to treat adult patients with metastatic non-small cell lung cancer whose disease has progressed after standard-of-care therapy. It was also approved in combination with BCG for adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease. The company disclosed these updates through press releases that are furnished as exhibits.
ImmunityBio, Inc. amended its existing Open Market Sale Agreement with Jefferies to expand its at-the-market stock offering program. The amendment authorizes the issuance of up to an additional $459,972,480 of common shares, which were registered under a new prospectus supplement dated December 23, 2025 and issued under the company’s effective Form S-3ASR shelf registration.
The company also highlighted that a previously approved Certificate of Amendment to its charter became effective on November 10, 2025, increasing authorized common shares from 1,350,000,000 to 1,650,000,000. Legal opinions and the amendment documents are filed as exhibits, supporting the validity of the newly registered shares and the updated ATM program.
ImmunityBio, Inc. is registering and may sell up to $459,972,480 of its common stock from time to time through Jefferies LLC under an at-the-market offering program. Jefferies will act as sales agent on commercially reasonable efforts terms and receive up to 3.0% of the gross proceeds as commission.
The company plans to use net proceeds, together with other funds, to continue commercializing its FDA- and MHRA‑approved bladder cancer therapy ANKTIVA, fund clinical trials and broader research and development, and support working capital and general corporate purposes, with potential use for licensing or acquisitions. Because shares will be sold into the market at prevailing prices, investors face risks of share price volatility, uncertain total proceeds, and dilution, including immediate and substantial dilution relative to net tangible book value illustrated in the filing.
ImmunityBio, Inc. director reported receiving a new stock option grant for 146,020 shares of common stock at an exercise price of $2.36 per share, expiring on December 12, 2035.
The award was granted under the 2025 Equity Incentive Plan and vests in three annual installments, with 48,673 options vesting on December 12, 2026, 48,673 on December 12, 2027 and 48,674 on December 12, 2028, as long as the director continues as a service provider.
Any unvested options will fully vest immediately before a Change in Control, as defined in the 2025 Equity Incentive Plan, if the director remains a service provider through that date.